NKTX Nkarta Inc

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

SVB Leerink 10th Annual Global Healthcare ConferenceFebruary 26, 2021Fireside chat presentation: 1:40 p.m. ETCowen 41st Annual Health Care ConferenceMarch 3-4, 2021No presentationBarclays Global Healthcare ConferenceMarch 11, 2021Fireside chat presentation: 10:20 a.m. ET

Live audio webcasts of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com. Replays of the webcasts will be archived on the website for approximately four weeks.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.gmann@nkartatx.com